about
Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studiesHypertriglyceridemia and Cardiovascular Diseases: RevisitedOptimizing outcomes during left main percutaneous coronary intervention with intravascular ultrasound and fractional flow reserve: the current state of evidenceIntravascular ultrasound in cardiovascular medicineEffect of torcetrapib on the progression of coronary atherosclerosisEffect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.Pain in the neck.Lipid Lowering Therapy to Modify Plaque Microstructures.Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasoundRegression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burdenMyeloperoxidase and cardiovascular disease.An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.Rosuvastatin and progression of atherosclerosis.Evolving targets for lipid-modifying therapyLowering triglycerides to modify cardiovascular risk: will icosapent deliver?Optimization of whispering gallery resonator design for biosensing applications.Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol.Antiinflammatory properties of HDL.Dynamic Self-Referencing Approach to Whispering Gallery Mode Biosensing and Its Application to Measurement within Undiluted Serum.Formation of dysfunctional high-density lipoprotein by myeloperoxidase.Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease: the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation StudyIntravascular ultrasound in the current percutaneous coronary intervention era.HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis.High-density lipoproteins: an emerging target in the prevention of cardiovascular disease.New targets of high-density lipoprotein therapy.Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?Achieving better modulation of coronary atherosclerosis: its understanding, visualization and treatment.Brain natriuretic peptides as biomarkers for atherosclerosis.Atherosclerotic plaque reduction: blood pressure, dyslipidemia, atherothrombosis.Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries.The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study.Heart failure after conventional metal-on-metal hip replacements.Future requirement for arterial wall imaging modalities in the evaluation of novel anti-atherosclerotic therapies.Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis.The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis.Biomarkers of inflammation and oxidative stress in atherosclerosis.
P50
Q26738588-BFF9833D-5C6C-4097-9099-5A7ED3225E38Q26750954-4D81C662-1C04-4D17-B3E2-121622014F31Q26861595-954C9BA9-63CD-450A-B71C-581803B1B8FAQ28199736-F6F211B2-3D20-4D4E-BA93-E3890D5EF55AQ28295023-7CA8894A-A197-402B-91B4-BC83ADF1E8EFQ30364133-66F8573F-497A-40FA-A62C-F7875498B871Q33148991-318B45BA-030E-4D41-BF45-F4BB6F8C0E6CQ33567290-EBA5C977-EA7D-4FD9-85F1-0E6B70576AC8Q33576435-FDAB622E-F128-464F-BDC2-5DF3E4E840E0Q33688005-4D5BA510-CFBB-4998-B5FF-F72B39CF5E3FQ33714672-D39B23F2-84B9-4F16-BB05-DA901DAEB0C3Q34406359-D6443609-5098-48AA-AB0D-C1E1118A4A24Q34481332-2CD294DE-DA80-417D-AE9C-FA509F80AF35Q34556647-FA2E09F9-85E2-4A89-8194-C48FDAF20B0AQ34655950-80549221-2914-46D1-BAA6-3F29C76845CCQ34802802-0920D81C-6211-4B74-8059-D24F9E323D86Q34880292-7CC7AE79-3C18-4B79-8314-ECE074BFC057Q35230819-D70C1881-7325-4EF4-A755-A200E24DE979Q35697638-A62EBBF3-1A91-43E8-AEBE-B58062709BAFQ35909357-1E19FB7B-E503-45DB-AD38-EE19DD6A0C67Q35915159-6B042671-5475-4DFB-B060-E85C9388B287Q35919164-20F16C41-4BE3-4BD7-B7E9-B3D195E6C284Q35949164-0DFF59F0-A5E0-4156-80B9-3ECE874F6D72Q36266928-2D7CE5B5-05ED-4A8F-BE75-7BD1DA334A12Q36351005-8BD107A3-FEA0-47CA-980D-0271A481A1AEQ36510135-B3C731CF-86CB-4EB0-BC53-6435FB1F5F8CQ36516383-5C50B8BE-EF1B-4F8D-87D2-E8BE6FADA519Q36611036-8314EB72-565C-46F1-9445-0B59ECAB77C1Q36874838-BCA86113-7863-40B6-BC87-9BB6A125FE61Q37049632-9CAE9512-288B-4599-991C-FD136BBA12B8Q37124164-FBE8A47B-A29E-4CEB-91BE-0A1D04614BD5Q37209349-FA2A3593-F46D-4798-8361-01ADD77C1295Q37366454-D0ED04EA-AF17-4865-B8F4-190FAC0CB6AEQ37547911-0FC534C3-9471-4941-A28A-2C302527BCCAQ37572118-39EC191A-FCB4-4EAF-8989-E75E2324AAC2Q37597154-CD03C83F-311B-461E-B054-B959CD8108CDQ37679198-B919AC0E-61CA-4B4B-BD6F-B177862C0137Q37679201-3584EEBF-6E5A-42FB-9E2D-A6BEFAC93482Q37704868-70D66700-5635-4089-B3C9-B91E96F48933Q37765284-718E1833-AA33-4CF8-A845-3324153DEEEE
P50
description
researcher
@en
wetenschapper
@nl
name
Stephen Nicholls
@en
Stephen Nicholls
@nl
type
label
Stephen Nicholls
@en
Stephen Nicholls
@nl
prefLabel
Stephen Nicholls
@en
Stephen Nicholls
@nl
P106
P31
P496
0000-0002-9668-4368